Abstract:n the united states, it is estimated that 30% of the 800,000 people living with hiv are coinfected with the hepatitis C virus (hcv). Similar rates have been documented in Western Europe, although the actual number of hiv-infected individuals in some countries is not well defined. The magnitude and potential ramifications of hiv/hcv-coinfection are even more alarming in Spain, where Dr. Vincent Soriano suggested that at least half of the 130,000 hiv-positive people in the country are coinfected with hcv (Soriano, 2000). In turn, Spain has become a hotbed of coinfection research and has yielded studies that have helped to address some of the most important questions regarding follow-up and treatment facing clinicians today. To appreciate the impact of liver disease on the lives (and deaths) of hiv-positive patients in the era of haart, Dr. Soriano reviewed data from several European and American retrospective studies that have been published over the past few years. In one study evaluating the impact of endstage liver disease in a cohort of hiv-infected patients—both before and after haart came into widespread use—Dr. Luis Martín-Carbonero, Dr. Soriano, and their colleagues conducted a review of medical charts detailing hospital admissions at the Hospital Carlos III in Madrid between January 1996 and December 2000 (MartínCarbonero, 2001). Discharge diagnosis, complications during the inpatient period, and the number and causes of death were recorded. A total of 1334 hospital admissions involving 875 hiv-infected patients were included in the analysis (three-quarters of these cases were associated with underlying hcv infection). Overall, 158 (11.8%) were admitted because of liver disease complications, or developed complications of liver disease during their admission for another reason. Most interesting were the number and proportion of admissions over time. In 1996, prior to the widespread use of haart, 31/330 (9.4%) admissions were related to liver disease. In 2000, however, 46/159 (29%) admissions were tied to liver complications. As for mortality rates, there were 54 deaths among admitted hiv-positive patients in 1996, five (9%) of which were related to liver disease. In 2000, there were 20 deaths, nine (45%) tied to liver disease. “In 2000, we had more deaths related to liver failure than we did to typical aids-related diseases,” Dr. Soriano added. “Unfortunately, Madrid is by no means alone in this trend. It is going on across Europe and throughout North America.” Studies with similar findings discussed by Dr. Soriano included one conducted in Brescia, Italy (Puoti, 2000), another conducted in Paris (Cacoub, 2001), and a third conducted in Boston (Bica, 2001) (see Table 1). The Significance of hiv/hcv Coinfection a large number of studies—many of which have been discussed in previous issues of The PRN Notebook—have demonstrated that hiv accelerates the clinical course of hcv disease. These studies, taken as a whole, add significant weight to the growing consensus that chronic hcv disease in hiv-infected patients truly is an opportunistic disease—an aids-defining illness now classified by the U.S. Centers for Disease Control. In a Seville-based retrospective analysis of 547 intravenous drug users with chronic hcv infection, patients coinfected with hiv progressed to cirrhosis faster than their hiv-negative counterparts (Soto, 1997). Within ten years after being infected with hcv, 13/87 (14.9%) hiv-positive subjects developed cirrhosis, in comparison with 7/272 (2.6%) patients infected only with hcv. The study also reported that the mean interval from the estimated time of hcv infection to cirrhosis was significantly longer in hiv-negative than hivpositive patients (23.2 vs. 6.9 years).

Proteomic Analysis of Palmitoylated Proteins in Human Colon Carcinoma Tissues

Abstract A06: Cholesteryl Ester Accumulation Induced by PTEN Loss and PI3K/AKT Activation Underlies Human Prostate Cancer Aggressiveness

Cholesteryl Ester Accumulation Induced by PTEN Loss and PI3K/AKT Activation Underlies Human Prostate Cancer Aggressiveness

Identification of Palmitoylated Transitional Endoplasmic Reticulum ATPase by Proteomic Technique and Pan Antipalmitoylation Antibody.

Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer.

Palmitoylation landscapes across human cancers reveal a role of palmitoylation in tumorigenesis

Comparative proteomic study for profiling differentially expressed proteins between Chinese left- and right-sided colon cancers.

[Palmitoylome Profiling Indicates That Androgens Promote the Palmitoylation of Metabolism-Related Proteins in Prostate Cancer-Derived LNCaP Cells].

Site-Specific Quantification of Protein Palmitoylation by Cysteine-Stable Isotope Metabolic Labeling.

Quantitative proteome analysis of colorectal cancer-related differential proteins

A Simple, Semi-Quantitative Acyl Biotin Exchange-Based Method to Detect Protein S-Palmitoylation Levels

Quantitative proteome analysis of tumor markers associated with colorectal cancer

Global-scale profiling of differential expressed lysine acetylated proteins in colorectal cancer tumors and paired liver metastases

Emerging roles of protein palmitoylation and its modifying enzymes in cancer cell signal transduction and cancer therapy

Insights into a Machine Learning-Based Palmitoylation-Related Gene Model for Predicting the Prognosis and Treatment Response of Breast Cancer Patients

High-throughput proteomics integrated with gene microarray for discovery of colorectal cancer potential biomarkers.

Molecular mechanism of palmitic acid and its derivatives in tumor progression

Liver Disease in HIV : An Update

Quantitative Proteomic Analysis of Aberrant Expressed Lysine Acetylation in Gastrointestinal Stromal Tumors

Protein Palmitoylation and Its Pathophysiological Relevance

The palmitoylation of AEG-1 dynamically modulates the progression of hepatocellular carcinoma